Impact of Hospital Pharmacist on Drug Management in Patients With Bronchopulmonary Cancer
NCT ID: NCT06469957
Last Updated: 2025-12-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
ACTIVE_NOT_RECRUITING
60 participants
OBSERVATIONAL
2024-06-25
2025-12-27
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In our context of shortage of care staff, with a polymedicated and elderly population, we would like to assess the impact of hospital pharmacist in the drug management for patient with bronchopulmonary cancers treated by these therapies.
Other French studies (Lille, Angers, Tours) involving hospital pharmacists were carried out and aimed to evaluate the number of pharmaceutical interventions carried out without assessing the impact on the patient. In addition, no study concerns the Center Val de Loire region.
The aim of the study is to impact of hospital pharmacist (interview) on the number of unscheduled consultations/hospitalizations.
This is a prospective, non-interventional study to evaluate impact of hospital pharmacist on drug management in patients with bronchopulmonary cancer. Participants will be included after being informed and after obtaining no opposition to participate. Data collection sheet will be performed by hospital pharmacist at inclusion. Participants will be treated according to standard of care for cancer treatment. An interview will be performed 1 month, 3 months and 6 months after inclusion between hospital pharmacist and participant to obtain information's on cancer treatments (questionnaires). These interviews will be performed by phone or when the patient comes to the hospital for a follow-up consultation as part of the treatment of his cancer (standard of care).
A total of 60 participants will be included in this study based on 1) the number of patients received a novel cancer treatment in the center during 12 months and 2) considered eligibility criteria, pharmacist availability and patients consent.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Questionnaires and data collection sheet
Questionnaires
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Patient without cognitive impairments
3. Patient with bronchopulmonary cancer
4. Patient treated by chemotherapy, immunotherapy or oral targeted therapy
Exclusion Criteria
2. Language barrier and lack of translator
3. Patient under guardianship, curatorship or deprived of liberty
4. Pregnant or breastfeeding women
5. Participation in any drug clinical drug trials
6. Patient with no insurance
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Régional d'Orléans
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Catherine DA VIOLANTE, Dr
Role: PRINCIPAL_INVESTIGATOR
CHU d'Orléans
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHU d'Orléans
Orléans, , France
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Babin M, Folliard C, Robert J, Sorrieul J, Kieffer H, Augereau P, Devys C. [Pharmaceutical consultations in oncology: Implementation, one-year review and outlooks]. Ann Pharm Fr. 2019 Sep;77(5):426-434. doi: 10.1016/j.pharma.2019.05.001. Epub 2019 Jul 7. French.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CHRO-2023-12
Identifier Type: -
Identifier Source: org_study_id